每(mei)經(jing)AI快訊，華東(dong)(dong)醫藥(yao)(yao)晚(wan)間公(gong)(gong)告，公(gong)(gong)司(si)全資子公(gong)(gong)司(si)中美(mei)華東(dong)(dong)收到國家(jia)藥(yao)(yao)品(pin)監督管理局(ju)（NMPA）核準簽發的藥(yao)(yao)物臨床(chuang)(chuang)試驗批準通知(zhi)書，由中美(mei)華東(dong)(dong)申(shen)報的HDM1005注射液臨床(chuang)(chuang)試驗申(shen)請獲得批準，該藥(yao)(yao)品(pin)適(shi)應癥為代謝相關(guan)脂(zhi)肪(fang)(fang)性肝病（MAFLD）/代謝相關(guan)脂(zhi)肪(fang)(fang)性肝炎（MASH）。